TABLE 2.

Lesion cure in BALB/c mice and GSH treated with known antileishmanial compounds^a

Compound tested	Dose (mg/kg)	No. of cured animals/total no. of animals tested
		BALB/c mice	GSH
AmBisome	12.5	4/5*	5/5*
AmBisome	25	5/5*	5/5*
Amphotericin B	6	1/5	2/6
Amphotericin B	8	3/5*	5/6*
Amphotericin B	16	5/5*	6/6*
ABLC	12.5	4/5*	NT
ABLC	25	5/5*	NT
ABLC	37.5	5/5*	NT
Paromomycin	50	NT	3/5*
Topical paromomycin		5/5*	NT
Topical WR279396		5/5*	5/5*

^aFive mice and five GSH were assigned to each treatment and vehicle-control group, except for the amphotericin B study, in which six GSH were assigned to each group. Treatment was initiated when lesions progressed to an average size of 50 mm² and 150 mm² for BALB/c mice and GSH, respectively. Drugs were given i.p. for 10 consecutive days, except for paromomycin, which was given i.p. for 7 days, and the two topical creams, paromomycin and WR279396, which were applied topically BID. The starting mean lesion sizes in the treatment groups were not statistically significantly different. Single-factor ANOVA (Dunnett's test) was used to determine whether the differences in the mean group lesion size existed on days 10 and 25 after the end of treatment for BALB/c mice and GSH, respectively. *, statistically significant difference (P < 0.05). Of note, all cures in GSH treated with known antileishmanial compounds happened before any of the BALB/c mice belonging to the vehicle-control group had self-healed. NT, not tested.